ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

OPTI Optibiotix Health Plc

14.50
-0.50 (-3.33%)
Last Updated: 10:14:56
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Optibiotix Health Plc LSE:OPTI London Ordinary Share GB00BP0RTP38 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50 -3.33% 14.50 14.00 15.00 15.00 14.50 15.00 77,263 10:14:56
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Noncomml Resh Organizations 644k -2.04M -0.0208 -6.97 14.69M

OptiBiotix Health PLC ProBiotix Health plc Fundraise

05/09/2024 10:32am

RNS Regulatory News


RNS Number : 0782D
OptiBiotix Health PLC
05 September 2024
 

OptiBiotix Health plc

("OptiBiotix" or the "Company" or "the Group")

 

ProBiotix Health plc Fundraise

 

OptiBiotix plc ("OptiBiotix") notes the announcement made by ProBiotix Health plc (AQSE: PBX) ("ProBiotix"), the life sciences business developing probiotics to support cardiometabolic health, on 4 September 2024, that it has raised £1,226,400 through a share subscription (the "Subscription").

The shares comprised in the Subscription appear to be issued pursuant to an authority purported to be taken from shareholders by ProBiotix Health plc at its annual general meeting held on 8 August 2024. However, OptiBiotix legal advisors have advised the Company that resolution 6 set out in ProBiotix's notice of annual general meeting (which has still not been filed at Companies House in breach of section 30 of the Companies Act 2006) contains a fundamental error (which was not brought to the attention of, or corrected by the requisite majority at the annual general meeting) by cross referencing the conditionality of resolution 6 to the passing of "Resolution 8" (which did not exist). The special resolution is accordingly invalid in accordance with section 283(6)(c), Companies Act 2006. OptiBiotix will bring this defect to the attention of AQUIS.

 

 

Neil Davidson, Chairman of OptiBiotix Health plc said: "Given previous public statements of sufficient funds by ProBiotix, OptiBiotix were surprised at the timing and level of discount of the Subscription and its highly dilutive effect on long term investors. OptiBiotix's legal advisors have explained that, as a consequence of the invalidity of the special resolution purportedly passed at the 2024 annual general meeting, ProBiotix do not currently have the right to issue equity on a non pre-emptive basis given that the prior authority taken at the 2023 annual general meeting expired at the conclusion of the 2024 annual general meeting. OptiBiotix will bring this matter to the attention of AQUIS."

 

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact: OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive


 


Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 


Peterhouse Capital Limited (Broker)

Tel: 020 7220 9797

Duncan Vasey / Lucy Williams




Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy


 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEUPUGWBUPCUBA

1 Year Optibiotix Health Chart

1 Year Optibiotix Health Chart

1 Month Optibiotix Health Chart

1 Month Optibiotix Health Chart

Your Recent History

Delayed Upgrade Clock